Drug Profile
Research programme: SHP2 inhibitors - Novartis Institutes for BioMedical Research
Alternative Names: SHP 065; SHP 156; SHP 393Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Novartis Institutes for BioMedical Research
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine phosphatase non receptor type 11 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Cancer in USA
- 01 Apr 2017 Preclinical trials in Cancer in USA (unspecified route)
- 01 Apr 2017 Preclinical data in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)